341 related articles for article (PubMed ID: 20870899)
1. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
[TBL] [Abstract][Full Text] [Related]
2. SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.
Koren-Michowitz M; Gery S; Tabayashi T; Lin D; Alvarez R; Nagler A; Koeffler HP
Br J Haematol; 2013 Jun; 161(6):811-20. PubMed ID: 23590807
[TBL] [Abstract][Full Text] [Related]
3. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.
Bersenev A; Wu C; Balcerek J; Tong W
J Clin Invest; 2008 Aug; 118(8):2832-44. PubMed ID: 18618018
[TBL] [Abstract][Full Text] [Related]
4. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
[TBL] [Abstract][Full Text] [Related]
5. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
[TBL] [Abstract][Full Text] [Related]
6. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
7. JAK2
Lin CH; Kaushansky K; Zhan H
Blood Cells Mol Dis; 2016 Nov; 62():42-48. PubMed ID: 27865175
[TBL] [Abstract][Full Text] [Related]
8. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
[TBL] [Abstract][Full Text] [Related]
9. JAK2-V617F is a negative regulation factor of SHIP1 protein and thus influences the AKT signaling pathway in patients with Myeloproliferative neoplasm (MPN).
Glück M; Dally L; Jücker M; Ehm P
Int J Biochem Cell Biol; 2022 Aug; 149():106229. PubMed ID: 35609769
[TBL] [Abstract][Full Text] [Related]
10. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic JAK2
Prestipino A; Emhardt AJ; Aumann K; O'Sullivan D; Gorantla SP; Duquesne S; Melchinger W; Braun L; Vuckovic S; Boerries M; Busch H; Halbach S; Pennisi S; Poggio T; Apostolova P; Veratti P; Hettich M; Niedermann G; Bartholomä M; Shoumariyeh K; Jutzi JS; Wehrle J; Dierks C; Becker H; Schmitt-Graeff A; Follo M; Pfeifer D; Rohr J; Fuchs S; Ehl S; Hartl FA; Minguet S; Miething C; Heidel FH; Kröger N; Triviai I; Brummer T; Finke J; Illert AL; Ruggiero E; Bonini C; Duyster J; Pahl HL; Lane SW; Hill GR; Blazar BR; von Bubnoff N; Pearce EL; Zeiser R
Sci Transl Med; 2018 Feb; 10(429):. PubMed ID: 29467301
[TBL] [Abstract][Full Text] [Related]
12. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M
FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730
[TBL] [Abstract][Full Text] [Related]
13. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
14. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
[TBL] [Abstract][Full Text] [Related]
15. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
16. Activating mutations in JAK2 and CALR differentially affect intracellular calcium flux in store operated calcium entry.
Bhuria V; Franz T; Baldauf C; Böttcher M; Chatain N; Koschmieder S; Brümmendorf TH; Mougiakakos D; Schraven B; Kahlfuß S; Fischer T
Cell Commun Signal; 2024 Mar; 22(1):186. PubMed ID: 38509561
[TBL] [Abstract][Full Text] [Related]
17. Preferential nuclear accumulation of JAK2V617F in CD34+ but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia.
Rinaldi CR; Rinaldi P; Alagia A; Gemei M; Esposito N; Formiggini F; Martinelli V; Senyuk V; Nucifora G; Pane F
Blood; 2010 Dec; 116(26):6023-6. PubMed ID: 20861460
[TBL] [Abstract][Full Text] [Related]
18. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
19. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
[TBL] [Abstract][Full Text] [Related]
20. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
